Mucosal Application of gp140 Encoding DNA Polyplexes to Different Tissues Results in Altered Immunological Outcomes in Mice

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Mann, Jamie F S ^a   McKay, Paul F ^a   Arokiasamy, Samantha ^a   Patel, Reeyeshkumar K ^b   Tregoning, John S ^a   Shattock, Robin J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CN54 GLYCOPROTEIN GP 140; DNA VACCINE; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; PLASMID DNA; POLYETHYLENEIMINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; B LYMPHOCYTE; COMPARATIVE STUDY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCING CELL; IMMUNOPROPHYLAXIS; INFLUENZA; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; POLYMERIZATION; SEROCONVERSION; VACCINATION; VAGINAL SECRETION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, SUBLINGUAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; NASAL MUCOSA; ORTHOMYXOVIRIDAE INFECTIONS; SPLEEN; VACCINATION; VACCINES, DNA;

MUS;

EID: 84879467577     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067412     Document Type: Article

References (31)

1. Neutra MR, Kozlowski PA, (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
2. De Calisto J, Villablanca EJ, Wang S, Bono MR, Rosemblatt M, et al. (2012) T-cell homing to the gut mucosa: general concepts and methodological considerations. Methods Mol Biol 757: 411-434.
3. Mora JR, von Andrian UH, (2008) Differentiation and homing of IgA-secreting cells. Mucosal Immunol 1: 96-109.
4. Minne A, Louahed J, Mehauden S, Baras B, Renauld JC, et al. (2007) The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology 122: 316-325.
5. Azizi A, Ghunaim H, Diaz-Mitoma F, Mestecky J, (2010) Mucosal HIV vaccines: a holy grail or a dud? Vaccine 28: 4015-4026.
6. Klavinskis LS, Gao L, Barnfield C, Lehner T, Parker S, (1997) Mucosal immunization with DNA-liposome complexes. Vaccine 15: 818-820.
7. Woodland DL, (2004) Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25: 98-104.
8. Lu S, (2006) Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 28: 255-265.
9. Mazumder S, Maji M, Das A, Ali N, (2011) Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS One 6: e14644.
10. Geiben-Lynn R, Greenland JR, Frimpong-Boateng K, van Rooijen N, Hovav AH, et al. (2008) CD4+ T lymphocytes mediate in vivo clearance of plasmid DNA vaccine antigen expression and potentiate CD8+ T-cell immune responses. Blood 112: 4585-4590.
11. Rush CM, Mitchell TJ, Garside P, (2010) A detailed characterisation of the distribution and presentation of DNA vaccine encoded antigen. Vaccine 28: 1620-1634.
12. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, et al. (2005) Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 79: 7933-7937.
13. Wu L, Kong WP, Nabel GJ, (2005) Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 79: 8024-8031.
14. Torrieri-Dramard L, Lambrecht B, Ferreira HL, Van den Berg T, Klatzmann D, et al. (2011) Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol Ther 19: 602-611.
15. Bivas-Benita M, Bar L, Gillard GO, Kaufman DR, Simmons NL, et al. (2010) Efficient generation of mucosal and systemic antigen-specific CD8+ T-cell responses following pulmonary DNA immunization. J Virol 84: 5764-5774.
16. Bivas-Benita M, Gillard GO, Bar L, White KA, Webby RJ, et al. (2013) Airway CD8(+) T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity. Mucosal Immunol.
17. Wei CJ, Xu L, Kong WP, Shi W, Canis K, et al. (2008) Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 82: 6200-6208.
18. Holmgren J, Czerkinsky C, (2005) Mucosal immunity and vaccines. Nat Med 11: S45-53.
19. Kantele A, Zivny J, Hakkinen M, Elson CO, Mestecky J, (1999) Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. J Immunol 162: 5173-5177.
20. Lindholm C, Naylor A, Johansson EL, Quiding-Jarbrink M, (2004) Mucosal vaccination increases endothelial expression of mucosal addressin cell adhesion molecule 1 in the human gastrointestinal tract. Infect Immun 72: 1004-1009.
21. Jiang H, Hester G, Liao L, Montefiori DC, Frank MM, (2010) Mechanisms by which HIV envelope minimizes immunogenicity. Immunol Res 49: 147-158.
22. Mann JF, Stieh D, Klein K, de Stegmann DS, Cranage MP, et al. (2012) Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen. J Control Release 158: 240-249.
23. Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, et al. (2012) Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One 7: e41144.
24. Richmond JF, Lu S, Santoro JC, Weng J, Hu SL, et al. (1998) Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 72: 9092-9100.
25. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, et al. (2001) The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75: 5526-5540.
26. Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, et al. (2011) Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS One 6: e24517.
27. Wang Z, Wang SX, Liu SY, Bao ZY, Zhuang DM, et al. (2009) Immunogenicities of Env glycoproteins from circulating HIV-1 isolates in China focusing on the strategy of "DNA prime plus protein boost". Chin Med J (Engl) 122: 2339-2345.
28. Buonaguro L, Devito C, Tornesello ML, Schroder U, Wahren B, et al. (2007) DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25: 5968-5977.
29. Yao XD, Fernandez S, Kelly MM, Kaushic C, Rosenthal KL, (2007) Expression of Toll-like receptors in murine vaginal epithelium is affected by the estrous cycle and stromal cells. J Reprod Immunol 75: 106-119.
30. Marks E, Helgeby A, Andersson JO, Schon K, Lycke NY CD4(+) T-cell immunity in the female genital tract is critically dependent on local mucosal immunization. Eur J Immunol 41: 2642-2653.
31. Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, et al. (2008) Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 105: 1644-1649.